Intravenously Administered Novel Liposomes, DCL64, Deliver Oligonucleotides to Cerebellar Purkinje Cells

Oligonucleotide therapy mitigates disease in Spinocerebellar Ataxia Type 3 mice

(2018) Hayley S. McLoughlin et al.   ANNALS OF NEUROLOGY

Use of Nanoparticles for Cerebral Cancer

(2018) Jörg Kreuter et al.   TUMORI

Antisense oligonucleotide therapy for spinocerebellar ataxia type 2

(2017) Daniel R. Scoles et al.   NATURE

RNAi prevents and reverses phenotypes induced by mutant human ataxin-1

(2016) Megan S. Keiser et al.   ANNALS OF NEUROLOGY

Brain-derived neurotrophic factor delivered to the brain using poly (lactide-co-glycolide) nanoparticles improves neurological and cognitive outcome in mice with traumatic brain injury

(2016) Igor Khalin et al.   DRUG DELIVERY

Role of scavenger receptors in peptide-based delivery of plasmid DNA across a blood–brain barrier model

(2016) Artita Srimanee et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistron

(2016) Yu Miyazaki et al.   Science Translational Medicine

Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3

(2016) Lodewijk J. A. Toonen et al.   Scientific Reports

Synthetic Nucleic Acids and Treatment of Neurological Diseases

(2016) David R. Corey   JAMA Neurology

Co-delivery of doxorubicin and siRNA for glioma therapy by a brain targeting system: angiopep-2-modified poly(lactic-co-glycolic acid) nanoparticles

(2015) Lei Wang et al.   JOURNAL OF DRUG TARGETING

Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study

(2015) Heike Jacobi et al.   LANCET NEUROLOGY

Peptide-like Polymers Exerting Effective Glioma-Targeted siRNA Delivery and Release for Therapeutic Application

(2015) Sai An et al.   Small

Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas

(2014) Zhen-Zhen Yang et al.   BIOMATERIALS

Nonallele Specific Silencing of Ataxin-7 Improves Disease Phenotypes in a Mouse Model of SCA7

(2014) Pavitra S Ramachandran et al.   MOLECULAR THERAPY

Consensus Paper: Pathological Mechanisms Underlying Neurodegeneration in Spinocerebellar Ataxias

(2013) A. Matilla-Dueñas et al.   CEREBELLUM

Adsorption of plasma proteins on uncoated PLGA nanoparticles

(2013) Karim Sempf et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Silencing Mutant ATXN3 Expression Resolves Molecular Phenotypes in SCA3 Transgenic Mice

(2013) Edgardo Rodríguez-Lebrón et al.   MOLECULAR THERAPY

Clinical Neurogenetics

(2013) Vikram G. Shakkottai et al.   NEUROLOGIC CLINICS

Liposomes to Target Peripheral Neurons and Schwann Cells

(2013) Sooyeon Lee et al.   PLoS One

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

(2012) Agnieszka Fiszer et al.   BMC MOLECULAR BIOLOGY

Transgenic Models of Spinocerebellar Ataxia Type 10: Modeling a Repeat Expansion Disorder

(2012) Karen N. McFarland et al.   Genes

Transgenic mice with SCA10 pentanucleotide repeats show motor phenotype and susceptibility to seizure: A toxic RNA gain-of-function model

(2011) Misti White et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Efficient In Vivo Delivery of siRNA Into Brain Capillary Endothelial Cells Along With Endogenous Lipoprotein

(2011) Hiroya Kuwahara et al.   MOLECULAR THERAPY

Transport across the Blood-Brain Barrier of Pluronic Leptin

(2010) T. O. Price et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: Influence of the formulation parameters

(2009) Svetlana Gelperina et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Delivery of small-interfering RNA (siRNA) to the brain

(2009) Saroj P Mathupala   EXPERT OPINION ON THERAPEUTIC PATENTS

Macromolecular drug transport into the brain using targeted therapy

(2009) Jacek Lichota et al.   JOURNAL OF NEUROCHEMISTRY

Safety Assessment of Poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, Poloxamer 105 Benzoate, and Poloxamer 182 Dibenzoate as Used in Cosmetics

(2008)   INTERNATIONAL JOURNAL OF TOXICOLOGY

Novel Therapeutic Modalities to Address Nondrugable Protein Interaction Targets

(2008) Errol B De Souza et al.   NEUROPSYCHOPHARMACOLOGY